GlassScriptPhysician profile
Lee J Goldstein
NPI 1164579181
$271,891.27
in general payments reported to CMS, 2019-2025
37 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $8,450 · 2021: $17K · 2022: $36K · 2023: $37K · 2024: $87K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Consulting Fee: $42K · Travel and Lodging: $24K · Food and Beverage: $7,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,612.50 |
| Consulting Fee | $42,087.50 |
| Travel and Lodging | $23,802.16 |
| Food and Beverage | $7,625.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $128,895.20 | 2019-2025 | Grafix, Grafix Pl, Stravix |
| Janssen Pharmaceuticals, INC | $54,442.91 | 2019-2023 | Xarelto |
| Pfizer INC. | $45,151.11 | 2019-2021 | |
| Lifenet Health | $17,564.07 | 2023-2025 | Theragenesis Wound Matrix |
| Bioventus LLC | $11,440.13 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $5,988.31 | 2019-2022 | |
| Lemaitre Vascular, INC. | $2,974.48 | 2019 | |
| Silk Road Medical, INC. | $1,067.59 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $970.50 | 2019-2025 | Crosser Iq, Rotarexs 6 F X 135 Cm |
| Kerecis Limited | $673.11 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $345.12 | 2019-2025 | Apligraf |
| Davol INC. | $310.63 | 2020-2021 | |
| Inari Medical, INC. | $265.73 | 2019-2022 | |
| Next Science LLC | $228.69 | 2022-2023 | Surgx, Xperience, Blastx |
| Medtronic Vascular, INC. | $194.33 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $173.87 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Hydrofera LLC | $153.46 | 2024-2025 | Hydrofera Blue, Cutimed Sorbact |
| Boston Scientific Corporation | $141.65 | 2020-2021 | |
| Cook Medical LLC | $140.85 | 2019 | |
| Shockwave Medical, INC | $116.63 | 2020 | |
| Medtronic, INC. | $85.74 | 2021-2022 | |
| Livanova USA, INC. | $75.68 | 2019 | |
| Kci USA, INC. | $67.30 | 2022-2023 | Tegaderm, Promogran Prisma, Snap |
| Solventum Corporation | $57.57 | 2024 | Promogran Prisma, Activ.A.C., Tegaderm |
| Tactile Systems Technology INC | $48.62 | 2019-2021 | |
| Aroa Biosurgery Incorporated | $48.26 | 2019 | |
| Angiodynamics, INC. | $42.09 | 2020-2021 | |
| Endologix LLC | $41.79 | 2019 | |
| Molnlycke Health Care US, LLC | $33.14 | 2024 | Mepilex, Exufiber Ag+, Mepilex Border Flex |
| Cardiovascular Systems INC. | $30.31 | 2019 | |
| Urgo Medical North America, LLC | $27.32 | 2025 | Urgok2 |
| Reprise Biomedical, INC. | $26.05 | 2023 | Miroderm, Miro3d |
| Mimedx Group, INC. | $21.73 | 2025 | |
| Convatec INC. | $17.03 | 2024 | |
| Biocompatibles, INC. | $15.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.